| Non-Alcoholic Fatty Liver Disease |
1 |
1 |
| Biliary Disease |
0 |
0.95 |
| Liver |
0 |
0.91 |
| Fatty Liver |
0 |
0.99 |
| Metabolic Syndrome |
0 |
0.82 |
| Hepatic Fibrosis |
0 |
0.71 |
| Aminotransferase |
0 |
0.68 |
| Liver Disease |
0 |
0.68 |
| Lipids Management |
0 |
0.39 |
| Steatosis |
0 |
0.25 |
| Statins |
0 |
0.98 |
| Blood |
0 |
0.1 |
| Body Mass Index |
0 |
0.1 |
| Insulin Resistance |
0 |
0.1 |
| Cardiovascular Risk Management |
0 |
0.05 |
| Clinical Research |
0 |
0.05 |
| Dyslipidemia |
0 |
0.05 |
| Europe |
0 |
0.05 |
| Healthcare and Medical Technology |
0 |
0.05 |
| Hospital |
0 |
0.05 |
| LDL Cholesterol |
0 |
0.05 |
| Magnetic Resonance Imaging |
0 |
0.05 |
| Nonalcoholic Steatohepatitis |
0 |
0.05 |
| Receptors |
0 |
0.05 |
| Triglycerides |
0 |
0.05 |
| Type 2 Diabetes Mellitus |
0 |
0.05 |
| Ultrasonography |
0 |
0.05 |